Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a 'Buy' rating on Recursion Pharmaceuticals (NASDAQ:RXRX), but lowers the price target from $17 to $15.
November 09, 2023 | 10:56 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst maintains a 'Buy' rating on RXRX but lowers the price target from $17 to $15.
The news is directly about Recursion Pharmaceuticals (RXRX). The 'Buy' rating is maintained which is positive, but the price target is lowered from $17 to $15, which might have a neutral to slightly negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100